Showing results (31-40 of 129) with videos related to

Sort By:
Pageof 13
Naunyn-Schmiedeberg'S Archives of Pharmacology|May 2, 2016
Pharmacological treatment options for mast cell activation diseaseGerhard J Molderings, Britta Haenisch, Stefan Brettner, et al.
Annals of Hematology|April 5, 2024
Quality of life after immune suppressive therapy in aplastic anemiaIris N Lommerse, Chris Hinnen, Liesbeth M van Vliet, et al.
Therapeutic Advances in Neurological Disorders|August 11, 2021
Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosisMaike F Dohrn, Gisa Ellrichmann, Rastislav Pjontek, et al.
International Journal of Molecular Sciences|August 29, 2024
Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow FunctionJeff Szer, Jens Panse, Austin Kulasekararaj, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 19, 2022
Imaging patterns of cerebral ischemia in hypereosinophilic syndrome: case report and systematic reviewKathrin Miethe, Elene Iordanishvili, Pardes Habib, et al.
Ejhaem|February 20, 2026
Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 InhibitorsShreyans Gandhi, Markus P Radsak, Yasutaka Ueda, et al.
Infection|April 4, 2023
Impact of the insertion site of central venous catheters on central venous catheter-related bloodstream infections in patients with cancer: results from a large prospective registryMarcus Hentrich, Boris Böll, Daniel Teschner, et al.
Blood Advances|February 5, 2024
Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNHMorag Griffin, Richard J Kelly, Jens Panse, et al.
Blood Advances|April 9, 2024
Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuriaRégis Peffault de Latour, Morag Griffin, Richard J Kelly, et al.
Plos One|July 30, 2024
Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitorsJens Panse, Nicolas Daguindau, Sonia Okuyama, et al.
Pageof 13